OncoMatch/Clinical Trials/NCT06593899
The Total Neoadjuvant Therapy for Soft Tissue Sarcoma of the Extremities
Is NCT06593899 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies 3 cycles of AI for soft tissue sarcomas.
Treatment: 3 cycles of AI — For localized soft tissue sarcomas (STS) of the extremities, limb-sparing or conservative surgery with perioperative radiotherapy (RT) is the standard of care. However, several challenges persist. Notably, there are exceedingly high rates of distant metastatic recurrence even after surgical resection and RT, and conventional fractionated radiotherapy has a prolonged duration (5-6 weeks). With advancements in RT technology, the gradual expansion of hypofractionated radiotherapy regimens enables significantly shorter treatment durations. Promising recent reports on 1-week hypofractionated RT regimens, such as the 5X5 Gy RT regimens, have demonstrated reasonable local control and acceptable toxicity in resectable STS.Addressing the challenge of distant metastasis, previous studies have indicated that AI regimens are expected to eliminate micrometastases and improve survival in patients with STS at a high risk of distant relapse. Therefore, the goal of this clinical trial is to investigate whether hypofractionated RT combined with a sequential chemotherapy（AI regimens）can enhance short-term treatment efficacy for extremity STS patients without compromising local control rates and increasing related toxicities
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy
Exception: previous history of radiotherapy to the same site
Previous history of radiotherapy to the same site
Cannot have received: cytotoxic chemotherapy
Previous exposure to chemotherapy
Lab requirements
Kidney function
severe renal insufficiency (Level IV) excluded
Liver function
severe liver insufficiency (Level IV) excluded
Cardiac function
grade III-IV cardiac insufficiency (NYHA standards) excluded
The function of major organs is normal; severe liver and renal insufficiency (Level IV) etc.; grade III-IV cardiac insufficiency (NYHA standards)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify